Why British American Tobacco Stock Jumped 11.6% in March

a man talking on a cell phone: Why British American Tobacco Stock Jumped 11.6% in March © Provided by The Motley Fool Why British American Tobacco Stock Jumped 11.6% in March

What happened

Shareholders of tobacco giant British American Tobacco (NYSE: BTI) had to be happy with the month of March, as shares gained 11.6% in the period, according to data provided by S&P Global Market Intelligence. That exceeds the approximately 9% returns for the entire past 12 months. Some of what investors like is the progress BAT is showing in diversifying from its traditional tobacco and nicotine products. 

So what

In mid-February, when the company reported its fiscal 2020 results, BAT updated investors on several aspects of its “new categories” segment. Its Vuse vapor revenue grew 85%, for example. But developments with its moves into cannabis-related products is what investors seem to be cheering the most.

a man talking on a cell phone: man vaping CBD product on British street © Getty Images man vaping CBD product on British street

In January 2021, BAT launched a pilot program in Manchester, U.K. for its first cannabidiol (CBD) vaping product, Vuse CBD Zone. And on March 11, the company announced it has entered into a strategic partnership with Canadian cannabis company Organigram Holdings (NASDAQ: OGI)

APPLE INC.

-0.34

-0.25%

CONSTELLATION BRANDS, INC.

+4.26

+1.82%

TESLA, INC.

+0.93

+0.13%

AMAZON.COM, INC.

+20.35

+0.60%

Now what

The Manchester CBD vaping product aims to offer adults BAT’s Vuse brand that “caters to a variety of moods and moments in their busy lifestyles,” according to the company. With its traditional vape products, BAT says it is growing market share already. In the U.S., BAT said it had over 60% market share by volume in the last quarter of 2020. It said Vuse is now the market leader in 15 U.S. states.  

But the deal with Organigram is what drove investor interest in March. The agreement calls for BAT to take an approximately 20% stake in Organigram. The $175 million investment includes plans for research and development collaboration with Organigram. The efforts will “focus on developing the next generation of cannabis products with an initial focus on CBD,” the companies said in a joint statement.

The company stressed that “This agreement augments ongoing BAT activities to expand its portfolio beyond nicotine.” It added, “This choice provides reduced risk alternatives to combustible cigarettes, as well as going beyond tobacco and nicotine into new and exciting areas of product innovation.”

The expansion beyond cigarettes, and even nicotine, is what investors seem to be looking for in the future with BAT. 

SPONSORED:

10 stocks we like better than British American Tobacco

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and British American Tobacco wasn’t one of them! That’s right — they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of February 24, 2021

 

Howard Smith has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends OrganiGram Holdings. The Motley Fool has a disclosure policy.

Author: CSN